How can we trick the immune system into overcoming the detrimental effects of oncolytic viral therapy to treat glioblastoma?

摘要

Although China approved the use of the H101 adenovirus for the treatment of various solid cancers in 2005, similar viruses have not obtained clinical approval in the USA [1]. While there are several Phase III trials testing the therapeutic efficacy of onc-olytic viruses (OVs) in patients diagnosed with melanoma, bladder and advanced head and neck cancers (ClinicalTrials.gov identifiers: NCT01438112, NCT00769704, NCT01166542 [101]), there are currently only Phase I/-II OV trials for patients with glioblastoma (GB), which highlights the difficulty associated with treating this particular disease (ClinicalTrials.gov identifiers: NCT00157703, NCT01174537, NCT00528684, NCT01301430, NCT-01582516 [101]).